Clinical Trial Update: Dose Escalation Study of Vandetanib With Hypofractionated Stereotactic Radiotherapy in Recurrent Malignant Gliomas [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation trial evaluating vandetanib with hypofractionated stereotactic radiotherapy for recurrent malignant gliomas has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• Vandetanib (vandetanib)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Malignant Gliomas | Phase 1 | Status: COMPLETED